← All stocks

Nuvectis Pharma, Inc.

NVCT Net buying

CIK 0001875558 #2767 in the set updated 17 Sep 2026

Bought (12 mo)

$2.29M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$2.29M

+$2.29M against sales at will

By person

9 insiders · 8 transactions

28.4×

Ron Bentsur holds 28.4 times base salary in stock. $73.77M of shares against $2.59M in salary for 2025.

Salary from the company's own proxy. The shares are what Ron Bentsur last reported holding, valued at $20.00, the price Common Stock was last bought or sold at on the open market here, on 30 Jun 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Mosseri Marlio Charles

10% owner

$1.87M (4)

—

+$1.87M

5,798,576

17.80%

$115.97M

+10.5%

BENTSUR RON

Chairman & CEO

$278.60K (2)

—

+$278.60K

3,688,424

11.32%

$73.77M

+13.6%

Sanchez Juan

Director

$75.27K (1)

—

+$75.27K

113,380

0.3480%

$2.27M

+220.5%

Kaplan Matthew L.

Director

$64.24K (1)

—

+$64.24K

159,760

0.4903%

$3.20M

+90.7%

Poradosu Enrique

Chief Science & Business Off

—

1,806,319

5.54%

$36.13M

+20.1%

Shemesh Shay

Chief Dev. & Ops. Officer

—

1,793,068

5.50%

$35.86M

+20.1%

Carson Michael J.

Vice President, Finance

—

230,118

0.7063%

$4.60M

+153.8%

Hoberman Kenneth

Director

—

168,140

0.5161%

$3.36M

+63.0%

Oliviero James F III

Director

—

122,828

0.3770%

$2.46M

+112.4%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 16

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 711,200

History held since 8 Feb 2022